LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer.


Selective up-regulation of the mRNA of LOXL4, a member of the LOX matrix amine oxidase family, significantly correlated with lymph node metastases and higher tumour stages in head and neck squamous cell carcinomas (HNSCC). To evaluate the diagnostic and prognostic value of the protein we produced an antibody specific for LOXL4 and assessed the expression in 317 human HNSCC specimens. The LOXL4 protein was detected in 92.7% of primary tumours, in 97.8% of lymph node metastases and in affected oral mucosa with high-grade dysplasia, but was absent in various non-neoplastic tissues of the head and neck. TNM categories and overall survival did not link to grades of immunoreactivity. Studies in cultured primary hypopharyngeal HTB-43 carcinoma cells detected perinuclear and cell surface expression of LOXL4, but no nuclear localisation. Therefore, its interactive SRCR-domains and catalytic activity combined with tumour cell specific expression and cell surface associated location indicate multiple functions in tumour cell adhesion and interactions with the extracellular matrix. Our data suggest that LOXL4 is useful both as tumour marker and target in the treatment of HNSCC.

DOI: 10.1016/j.ejca.2008.03.026
Citations per Year

286 Citations

Semantic Scholar estimates that this publication has 286 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Weise2008LOXL4IA, title={LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer.}, author={Jan Bernd Weise and Pierre Rudolph and Axel Heiser and M L Kruse and Juergen Hedderich and Christian Cordes and Markus Hoffmann and Ommo Brant and Petra Ambrosch and Katalin Csisz{\'a}r and Tibor Peter G{\"{o}r{\"{o}gh}, journal={European journal of cancer}, year={2008}, volume={44 9}, pages={1323-31} }